Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to $116.8 million.

  • Syndax Pharmaceuticals' Cash & Equivalents fell 12.19% to $116.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.8 million, marking a year-over-year decrease of 12.19%. This contributed to the annual value of $154.1 million for FY2024, which is 47.84% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Cash & Equivalents of $116.8 million as of Q3 2025, which was up 7.52% from $108.6 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash & Equivalents peaked at $295.4 million during Q4 2023, and registered a low of $57.5 million during Q1 2023.
  • Over the past 3 years, Syndax Pharmaceuticals' median Cash & Equivalents value was $114.6 million (recorded in 2024), while the average stood at $130.1 million.
  • Data for Syndax Pharmaceuticals' Cash & Equivalents shows a peak YoY increase of 297.27% (in 2023) and a maximum YoY decrease of 69.55% (in 2023) over the last 5 years.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $222.1 million in 2021, then crashed by 66.52% to $74.4 million in 2022, then soared by 297.27% to $295.4 million in 2023, then slumped by 47.84% to $154.1 million in 2024, then fell by 12.19% to $116.8 million in 2025.
  • Its Cash & Equivalents stands at $116.8 million for Q3 2025, versus $108.6 million for Q2 2025 and $154.0 million for Q1 2025.